Table 2.
Whole brain analyses of lorazepam during decision phase (effect on Risky versus Safe responses).
| X | y | z | L/R | Area | BA | F-value |
|---|---|---|---|---|---|---|
| Main Effect of Task: Risky-Safe Option | ||||||
| −43 | 8 | 26 | L | Inferior Frontal Gyrus / Anterior Insula |
9 13 |
39.98 |
| 1 | −10 | 4 | R | Thalamus | 47.52 | |
| 41 | 11 | 24 | R | Inferior Frontal Gyrus Anterior Insula |
9 13 |
40.25 |
| 1 | 12 | 38 | R | Cingulate Gyrus | 32 | 31.12 |
| 16 | −63 | 39 | R | Precuneus | 7 | 31.39 |
| −55 | −31 | 23 | L | Inferior Parietal Lobule | 40 | 35.08 |
| 50 | −32 | 6 | R | Superior Temporal Gyrus | 22 | 36.55 |
| −9 | −61 | 49 | L | Precuneus | 7 | 19.06 |
| 0 | −27 | 24 | R | Cingulate Gyrus | 23 | 31.30 |
| −27 | −71 | 27 | L | Precuneus | 31 | 17.99 |
| Nonlinear Dose Effect of Lorazepam | ||||||
| 57 | 24 | −14 | R | Inferior Frontal Gyrus | 47 | 8.34 |
| 18 | 3 | 44 | R | Cingulate Gyrus | 24 | 12.95 |
| 14 | 27 | 6 | R | Caudate | 7.30 | |
| −39 | 14 | 44 | L | Middle Frontal Gyrus | 6 | 6.61 |
| Linear Dose Effect of Lorazepam | ||||||
| 27 | −38 | −15 | R | Fusiform Gyrus | 37 | 5.65 |
| 9 | −4 | 40 | R | Cingulate Gyrus | 24 | 8.21 |
| 50 | −11 | 28 | R | Precentral Gyrus | 6 | 11.92 |
| −18 | 26 | 47 | L | Superior Frontal Gyrus | 8 | 3.46 |
| −8 | −2 | 5 | L | Thalamus | 4.72 | |
| 32 | 41 | 16 | R | Middle Frontal Gyrus | 10 | 4.51 |
| −21 | 1 | −11 | L | Parahippocampal Gyrus | 34 | 4.05 |
| −39 | 7 | 1 | L | Insula | 13 | 6.59 |
| 9 | 7 | 11 | R | Caudate | 4.19 | |